Shionogi and F2G Report Favorable Phase 3 Trial Data for Olorofim in Invasive Aspergillosis

Shionogi & Co., Ltd. and F2G Ltd. have disclosed positive exploratory analyses from their global Phase 3 OASIS study. The trial evaluated olorofim, an investigational oral antifungal, for treating invasive aspergillosis. These promising results are scheduled for presentation at IDWeek 2026, potentially advancing a new treatment option for this serious fungal infection.